"The method does not make any therapy without any improvement." With these words, in 2005, Dr. Cleveland's manuscript was rejected by a publication called the Natural Treatment. In the paper, Professor explained Medicine Neuropsychology, San Diego, a University of California University, a new way of digestational nervous depression, amortrophic lateral sclerosis (ALS) – the death of world famous physicist Stephen Hawking until his death. Cleveland and his team performed in experiments with the mouse. The disease is called the DNA drug.
Today, 13 years later, Donald Cleveland developed the use of the novel therapy patients. Several clinical trials are being conducted with DNA designer drugs. Not only is it not only in the form of ALS, but also by genetic disease Huntington's disease, Alzheimer's or Frederbergen Dementia, and other neurodegenerative diseases.
This peat is always the same: Make designer DNA medications, make sure that they are making sure the so-called "protein production" called antennae oligonioliides (ASO). For example, in Alzheimer's or Freetormopel dementia, it is a protein "to", which can aggravate the biodiesel in the nervous system and can cause cell death.
The DNA drug market for meat is wasted
A new diabetic disease, mesculine mussulal asteroids (SMA) and new DNA medicine have already reached patients. In this tradition, the so-called motor neurons will not work properly, and they are those neurons that move the muscles from the backbone. This is because of a wrong protein. As a result, the motor absorbs the entire muscles and the entire muscle.
The babies born in the largest form of the SMS can not rise or swear, they try to swallow and swallow. Usually they do not survive the second birthday. Last year, drug abuse was approved by a drug. The drug Spinraza (manufacturer bacon) based on the theory developed by Cleveland, some muscles reducing large amounts of mass, and some clinical children generally develop.
Stephen Hawking infected ALS should be treated immediately. Photo: Gatey
ALS and Alzheimer's and other neurodegenerative diseases take a few years to see whether the success of new DNA medicines is so stunning. They will always be based on hope. For example, Huntington. In early April, Roche, a pharmaceutical pharmaceutical company, offered a first clinical trial of the development and marketing of medicine from the California biotech firm Aynos. Roche plans to conduct a major clinical trial at the end of 2018 or at the start of 2019. "We know that the drug is safe," Cleveland says, "I hope the patients will benefit from it."
Cleveland's tough stand. Just a few years ago, DNA was used. He ridiculed the idea of exhausting excessive inactivity or wrong genes in snippets. Thus he tried to reduce the production of protein, "Swiss Nomis Foundation" in October. She admitted that cell biology was not finally working on textbooks. "Fibers seem to not read cells," he adds into a skin. He remembers an incident that was immediately mentioned by refusing his manuscript of "Nature Medicine".
In his paper Protein «Town»
Quouwe is now with a good laughter, and he and his team in San Diego's Louis Institute for Institut have developed a method that allows them to deal with other diseases in the future – that's what the catalog says globablestoma, about the current leukemia. Last year, Cleveland got a 3 million bracket prize. Now the price of the Nomis Foundation. Praised Cleveland at the award ceremony. "You're the first scientist to bring out treatments against clinicians of the clinic, the neurodegenic diseases," said Christian Hass, researcher of Alzheimer's, University of Munich.
The research was always a professional for Don Cleveland. "I always wanted to be a scientist," he says, "and I can not remember anything else." Cleveland grew up with two sisters in Mexico, not far from Mexico. His father taught physics in a local college. One of his sisters today is chemistry. Cleveland initially studied physics, but he adopted biochemistry during his PhD thesis at Princeton. During this period he performed his first song: Protein "Tow" in 1977, protein in the Alzheimer's, boxer, and the "disease of chronic trmatic encephalopathy" (CTET) of the disease in the Alzheimer's disease.
Later, he attempted to explain the complex system of cell division, the basic process of biology.
His career started well. It continued on a similar platform. He was the first person to be isolating and describing genes for the proteins called keratin (hair), actin (muscle) or tubulin (cystos clean). Later, he attempted to explain the complex system of cell division, the basic process of biology. Since then the DNA Drugs The development of DNA medications is just neurodegenerative diseases.
The 68-year-old's new concept is already going on: Cleveland wants to reset the new nerves in the brain. Dementia diseases such as Alzheimer's, Parkinson's, or CTET kill countless cells. As a rule, it still has support cells, called astrocytes, which, unlike the nag cells, easily regrow. His team has now succeeded in using DNA as a way for astrologers to turn to nerves. They were properly covered with mice, says Cleveland. "I never expected it." But it is different in textbooks.
(Editors and thermodynamics)
Created: 16.11.2018, 19:16 Clock